NCT06832722 - Procizumab (PCZ; AK1967) in Critical Cardiovascular Care | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

July 13, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 1, 2026

Conditions

Shock, Cardiogenic

Interventions

DRUG

AK1967 (Procizumab)

DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)

DRUG

Placebo

Application of placebo

Trial Locations (11)

RECRUITING

University Hospital Saint Pierre, Brussels

RECRUITING

General University Hospital in Prague - FVN, Prague

RECRUITING

Institute of Clinical and Experimental Medicine - IKEM, Prague

RECRUITING

University Hospital Avicenne AP-HP, Bobigny

RECRUITING

University Hospital Lille - Institut Cœur Poumon, Lille

RECRUITING

University Hospital - Dupuytren Limoges, Limoges

RECRUITING

Regional University Hospital Nancy - Hopitaux de Brabois, Nancy

RECRUITING

Lariboisière Hospital AP-HP, Paris

RECRUITING

Radboud University Medical Center, Nijmegen

RECRUITING

Clinical University Hospital Poznań, Poznan

RECRUITING

J. Mikulicz Radecki Clinical University Hospital Wrocław, Wroclaw